SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    [No authors listed] A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997; 89: 3909-3918.
  • 2
    McLaughlin P, Fuller L, Redman J, et al. Stage I-II low-grade lymphomas: a prospective trial of combination chemotherapy and radiotherapy. Ann Oncol. 1991; 2( suppl 2): 137-140.
  • 3
    Gospodarowicz MK, Bush RS, Brown TC, Chua T. Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys. 1984; 10: 489-497.
  • 4
    MacManus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol. 1996; 14: 1282-1290.
  • 5
    Wilder RB, Jones D, Tucker SL, et al. Long-term results with radiotherapy for stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys. 2001; 51: 1219-1227.
  • 6
    Pendlebury S, el Awadi M, Ashley S, Brada M, Horwich A. Radiotherapy results in early stage low grade nodal non-Hodgkin's lymphoma. Radiother Oncol. 1995; 36: 167-171.
  • 7
    Guadagnolo BA, Li S, Neuberg D, et al. Long-term outcome and mortality trends in early-stage, grade 1-2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2006; 64: 928-934.
  • 8
    Petersen PM, Gospodarowicz M, Tsang R, et al. Long-term outcome in stage I and II follicular lymphoma following treatment with involved field radiation therapy alone [abstract]. J Clin Oncol. 2004; 22: 14S(July 15 suppl). Abstract 6521.
  • 9
    Dreyling M. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009; 20( suppl 4): iv119-iv120.
  • 10
    Zelenetz AD, Advani RH, Buadi F, et al. National Comprehensive Cancer Network. Non-Hodgkin's Lymphoma Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2006; 4: 258-310.
  • 11
    Zelenetz AD, Advani RH, Byrd JC, et al. National Comprehensive Cancer Network. Non-Hodgkin's lymphomas. J Natl Compr Canc Netw. 2008; 6: 356-421.
  • 12
    Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol. 2009; 27: 1202-1208.
  • 13
    National Cancer Institute. Adult Non-Hodgkin Lymphoma Treatment. Physicians' Data Query (PDQ) comprehensive cancer database. Bethesda, Md: National Cancer Institute; 2009. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/adult-non-hodgkins/HealthProfessional/page6. Accessed April 20, 2009.
  • 14
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 15
    SPSS Inc. SPSS for Windows 14.0. Chicago, Ill: SPSS Inc.; 2005.
  • 16
    Winter JN, Gascoyne RD, Van Besien K. Low-grade lymphoma. Hematology Am Soc Hematol Educ Program. 2004; 2004: 203-220.
  • 17
    Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004; 104: 1258-1265.
  • 18
    Buske C, Gisselbrecht C, Griben J, Letai T, McLaughlin P, Wilson W. Refining the treatment of follicular lymphoma. Leuk Lymphoma. 2008; 49( suppl 1): 18-26.
  • 19
    Salles GA. Clinical features, prognosis and treatment of follicular lymphoma. Hematology Am Soc Hematol Educ Program. 2007; 2007: 216-225.
  • 20
    National Comprehensive Cancer Network, Inc. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Non-Hodgkin's Lymphomas. Jenkintown, Pa: National Comprehensive Cancer Network, Inc.; 2009. Available at: http://www.nccn.org/professionals/physician_ gls/PDF/nhl.pdf. Accessed September 29, 2009.
  • 21
    Girinsky T, van der Maazen R, Specht L, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol. 2006; 79: 270-277.
  • 22
    Campbell BA, Voss N, Pickles T, et al. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size. J Clin Oncol. 2008; 26: 5170-5174.